Cargando…
Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept betwee...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313094/ https://www.ncbi.nlm.nih.gov/pubmed/35884786 http://dx.doi.org/10.3390/biomedicines10071480 |
_version_ | 1784753994850107392 |
---|---|
author | Mena-Vázquez, Natalia Rojas-Gimenez, Marta Fuego-Varela, Clara García-Studer, Aimara Perez-Gómez, Nair Romero-Barco, Carmen María Godoy-Navarrete, Francisco Javier Manrique-Arija, Sara Gandía-Martínez, Myriam Calvo-Gutiérrez, Jerusalem Morales-Garrido, Pilar Mouriño-Rodriguez, Coral Castro-Pérez, Patricia Añón-Oñate, Isabel Espildora, Francisco Aguilar-Hurtado, María Carmen Hidalgo Conde, Ana Arnedo Díez de los Ríos, Rocío Cabrera César, Eva Redondo-Rodriguez, Rocío Velloso-Feijoo, María Luisa Fernández-Nebro, Antonio |
author_facet | Mena-Vázquez, Natalia Rojas-Gimenez, Marta Fuego-Varela, Clara García-Studer, Aimara Perez-Gómez, Nair Romero-Barco, Carmen María Godoy-Navarrete, Francisco Javier Manrique-Arija, Sara Gandía-Martínez, Myriam Calvo-Gutiérrez, Jerusalem Morales-Garrido, Pilar Mouriño-Rodriguez, Coral Castro-Pérez, Patricia Añón-Oñate, Isabel Espildora, Francisco Aguilar-Hurtado, María Carmen Hidalgo Conde, Ana Arnedo Díez de los Ríos, Rocío Cabrera César, Eva Redondo-Rodriguez, Rocío Velloso-Feijoo, María Luisa Fernández-Nebro, Antonio |
author_sort | Mena-Vázquez, Natalia |
collection | PubMed |
description | Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2–42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03–3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70–0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72–0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile. |
format | Online Article Text |
id | pubmed-9313094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93130942022-07-26 Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease Mena-Vázquez, Natalia Rojas-Gimenez, Marta Fuego-Varela, Clara García-Studer, Aimara Perez-Gómez, Nair Romero-Barco, Carmen María Godoy-Navarrete, Francisco Javier Manrique-Arija, Sara Gandía-Martínez, Myriam Calvo-Gutiérrez, Jerusalem Morales-Garrido, Pilar Mouriño-Rodriguez, Coral Castro-Pérez, Patricia Añón-Oñate, Isabel Espildora, Francisco Aguilar-Hurtado, María Carmen Hidalgo Conde, Ana Arnedo Díez de los Ríos, Rocío Cabrera César, Eva Redondo-Rodriguez, Rocío Velloso-Feijoo, María Luisa Fernández-Nebro, Antonio Biomedicines Article Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2–42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03–3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70–0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72–0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile. MDPI 2022-06-22 /pmc/articles/PMC9313094/ /pubmed/35884786 http://dx.doi.org/10.3390/biomedicines10071480 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mena-Vázquez, Natalia Rojas-Gimenez, Marta Fuego-Varela, Clara García-Studer, Aimara Perez-Gómez, Nair Romero-Barco, Carmen María Godoy-Navarrete, Francisco Javier Manrique-Arija, Sara Gandía-Martínez, Myriam Calvo-Gutiérrez, Jerusalem Morales-Garrido, Pilar Mouriño-Rodriguez, Coral Castro-Pérez, Patricia Añón-Oñate, Isabel Espildora, Francisco Aguilar-Hurtado, María Carmen Hidalgo Conde, Ana Arnedo Díez de los Ríos, Rocío Cabrera César, Eva Redondo-Rodriguez, Rocío Velloso-Feijoo, María Luisa Fernández-Nebro, Antonio Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease |
title | Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease |
title_full | Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease |
title_fullStr | Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease |
title_full_unstemmed | Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease |
title_short | Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease |
title_sort | safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313094/ https://www.ncbi.nlm.nih.gov/pubmed/35884786 http://dx.doi.org/10.3390/biomedicines10071480 |
work_keys_str_mv | AT menavazqueznatalia safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT rojasgimenezmarta safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT fuegovarelaclara safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT garciastuderaimara safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT perezgomeznair safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT romerobarcocarmenmaria safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT godoynavarretefranciscojavier safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT manriquearijasara safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT gandiamartinezmyriam safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT calvogutierrezjerusalem safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT moralesgarridopilar safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT mourinorodriguezcoral safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT castroperezpatricia safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT anononateisabel safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT espildorafrancisco safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT aguilarhurtadomariacarmen safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT hidalgocondeana safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT arnedodiezdelosriosrocio safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT cabreracesareva safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT redondorodriguezrocio safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT vellosofeijoomarialuisa safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease AT fernandeznebroantonio safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease |